Peptides for Cardiovascular Health & Heart Protection

Cardiovascular disease (CVD) remains the UK's leading cause of death, accounting for approximately 160,000 deaths annually. While statins, antihypertensives, and lifestyle modification are the cornerstone of prevention, research into peptide-based cardiovascular protection is expanding — driven in part by the unexpected cardiovascular benefits observed with GLP-1 agonists.

The SUSTAIN-6 and SELECT trials demonstrated that semaglutide significantly reduces major adverse cardiovascular events (heart attack, stroke, cardiovascular death) by 20-26%, even in non-diabetic patients. This has transformed our understanding of peptide therapeutics in cardiovascular medicine.

Natriuretic peptides (BNP, ANP) are endogenous peptide hormones that regulate blood pressure and fluid balance, and are already used as diagnostic biomarkers for heart failure. Research explores whether augmenting natriuretic peptide signalling could provide therapeutic benefits.

All information is educational. Cardiovascular health should be managed per NICE CG181 (lipid modification) and NG136 (hypertension) under GP or cardiologist supervision.